Nektar Therapeutics 3Q 2026: Revenue $9.39M, EPS ($1.63) — 10-Q Summary
Nektar Therapeutics reported 3Q 2026 revenue of $9.39M, down 20% YoY, and a net loss of $55.65M, up 57% YoY. Higher R&D and G&A expenses drove the loss, partly offset by interest income and restructuring benefits. The company advanced Phase 3 trials for rezpegaldesleukin and reported $952.9M in cash and investments.
How this was made

The 30-second read
Why it matters
The earnings miss may trigger short‑term sell pressure, but strong cash position and potential litigation recovery provide upside catalysts.
Market read
Primary earnings disclosure for a micro‑cap biotech; relevant for traders tracking biotech earnings momentum.
What to watch
Lilly verdict award of $90M could offset some loss if upheld on appeal.
Background
Nektar Therapeutics filed its Q3 2026 10‑Q, reporting a revenue decline and larger net loss, with ongoing Phase 3 trials and a pending litigation award.
Ticker impact
10-Q shows Q3 revenue down 20% YoY to $9.39M and net loss widening 57% to $55.65M.
likely downside as market prices in weaker revenue and higher loss
Revenue decline and loss expansion are material negative surprises for a micro‑cap biotech.
Market effects
Biotech sector may see modest pullback on earnings disappointment.
US biotech investors may reduce exposure to early‑stage therapeutic firms.
Limited; primarily affects US‑listed biotech investors.
Counterpoint
Cash runway of $952.9M suggests sufficient liquidity to fund upcoming Phase 3 trials, potentially supporting a rebound.
Key entities
- companyNektar Therapeutics
US‑listed biotech (NASDAQ: NKTR) reporting Q3 2026 results.

